A Prospective Study Comparing the Outcomes and Health-Related Quality of Life in Adult Patients with Myeloid Malignancies Undergoing Allogeneic Transplantation.

Slides:

Advertisements

Similar presentations

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

Advertisements

Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies Marcelo C. Pasquini,

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.

Vaccination of Children following Allogeneic Stem Cell Transplantation

Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk.

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.

Validation of National Institutes of Health Global Scoring System for Chronic Graft- Versus-Host Disease (GVHD) According to Overall and GVHD-Specific.

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies Katarina Le.

Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Outcomes of Hematopoietic Cell Transplantation in Adult Patients with Acquired Aplastic Anemia Using Intermediate-Dose Alemtuzumab-Based Conditioning

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Dynamic Detection of Anti–Human Leukocyte Antigen (HLA) Antibodies but not HLA-DP Loci Mismatches Can Predict Acute Graft-versus-Host Disease and Overall.

Biology of Blood and Marrow Transplantation

Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage.

Benefit of Allogeneic Transplantation in Patients Age ≥ 60 Years with Acute Myeloid Leukemia Is Limited to Those in First Complete Remission at Time of.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute.

John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.

Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic Leukemia

Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies Ensi Voshtina,

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System Paul D. Harker-Murray,

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma:

A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic.

Moderate/Severe Grade of Chronic Graft Versus Host Disease and Younger Age (Less Than 45 Years Old) Are Risk Factors for Avascular Necrosis in Adult Patients.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation? Melhem.

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

Similar Outcomes of Cryopreserved Allogeneic Peripheral Stem Cell Transplants (PBSCT) Compared to Fresh Allografts Dong Hwan Kim, Nazir Jamal, Ronnie.

Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin–Conditioned Hematopoietic Cell Transplantation Amit Kalra,

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is.

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance Deborah.

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older Vikas Gupta, Andrew Daly,

Peripheral Blood Eosinophilia Has a Favorable Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation Dong.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation Jennifer Beswick, Elizabeth.

Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients.

Blood and Marrow Transplant Handbook

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation

Reduced Intensity Versus Myeloablative Conditioning Allogeneic HCT for Relapsed/Refractory Lymphoma: Applying Refined Disease Risk Index (DRI) to Improve.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic.

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, Julie Aldridge,

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Presentation transcript:

A Prospective Study Comparing the Outcomes and Health-Related Quality of Life in Adult Patients with Myeloid Malignancies Undergoing Allogeneic Transplantation Using Myeloablative or Reduced-Intensity Conditioning Vikas Gupta, Tony Panzarella, Le Li, Jabeen Khan, Ajay Sharma, Jeffrey H. Lipton, John Kuruvilla, Hans Messner, Shabbir M.H. Alibhai Biology of Blood and Marrow Transplantation Volume 18, Issue 1, Pages 113-124 (January 2012) DOI: 10.1016/j.bbmt.2011.05.022 Copyright © 2012 Terms and Conditions

Figure 1 Comparisons of patients undergoing myeloablative versus RIC for HCT. (A) PFS. (B) OS. (C) Cumulative incidence of NRM. (D) Cumulative incidence of relapse. Biology of Blood and Marrow Transplantation 2012 18, 113-124DOI: (10.1016/j.bbmt.2011.05.022) Copyright © 2012 Terms and Conditions

Figure 2 Longitudinal comparisons of HRQOL of patients undergoing myeloablative versus RIC in various domains of EORTC-QLQ-C30. (A) Global QOL score. (B) Physical functioning. (C) Role functioning. (D) Social functioning. (E) Cognitive functioning. (F) Emotional functioning. Biology of Blood and Marrow Transplantation 2012 18, 113-124DOI: (10.1016/j.bbmt.2011.05.022) Copyright © 2012 Terms and Conditions

Figure 3 Longitudinal comparisons of HRQOL of patients undergoing myeloablative versus RIC. (A) FACT-An (80-point scale). (B) FACT-BMT (40-point scale). Biology of Blood and Marrow Transplantation 2012 18, 113-124DOI: (10.1016/j.bbmt.2011.05.022) Copyright © 2012 Terms and Conditions